Microalbuminuria (MA) is a predictor of excess cardiovascular morbidity and mortality in non-diabetic hypertensive patients. This study evaluated the electrocardiographic correlates of MA in adult non-diabetic Nigerians with essential hypertension. Ninety-six newly diagnosed hypertensive patients who consented and met the inclusion criteria for the study were recruited. Ninety-six age- and gender-matched normotensive controls were also studied. Resting 12-lead electrocardiogram of all patients and controls was done and the tracings analyzed by the authors for left ventricular hypertrophy with or without repolarization abnormalities, QTc prolongation, conduction abnormalities and cardiac arrhythmias such as atrial fibrillation. MA was present in 31 (32.3%) of the hypertensive patients and in only six (6.25%) of the normotensive controls. Electrocardiographic left ventricular hypertrophy (ECG LVH) was significantly more commonly found in patients with MA than in patients without it (74.2% vs 40%, p = 0.002). Left ventricular hypertrophy with ischemic pattern was significantly more frequent in the microalbuminuric hypertensive subset than in non-microalbuminuric patients (32.3% vs 13.8%, p = 0.03). The mean QTc were 0.464 +/- 0.02 s and 0.428 +/- 0.017 s for microalbuminuric and non-microalbuminuric patients respectively (p = 0.01). This study shows that MA is associated with ECG abnormalities such as left ventricular hypertrophy, ischemic pattern ST-T changes and QTc prolongation. This subset of hypertensive patients constitutes a higher risk group and needs intensive monitoring and follow-up. Screening for MA should constitute part of the routine investigation of adult Nigerians with hypertension.
Download full-text PDF |
Source |
---|
J Trauma Nurs
January 2025
Author Affiliations: Department of Neurosurgery (Dr Xiao), Department of Nursing Care, Affiliated Hospital of Chengdu University, Chengdu, China (Dr Wang).
Background: Traditional nursing care often fails to meet the complex needs of hypertensive cerebral hemorrhage patients. Limited evidence exists on the efficacy of structured nursing frameworks such as the Omaha System in postoperative care for these patients.
Objective: This study aims to evaluate the efficacy of Omaha-based extended nursing care in improving patients' outcomes.
Kidney360
January 2025
Division of Nephrology and Hypertension, Department of Internal Medicine, University of Kansas Medical Centre, 3901 Rainbow Blvd, MS3002, Kansas City, KS, USA.
Background: Patient involvement in research can help to ensure that the evidence generated aligns with their needs and priorities. In the Establishing Meaningful Patient-Centered Outcomes With Relevance for Patients with Polycystic Kidney Disease (EMPOWER PKD) project we aimed to identify patient-important outcomes and discuss the impact of PKD on patients.
Methods: Nine focus groups were held with adult patients with PKD, caregivers, and clinical or research experts in PKD.
J Invasive Cardiol
January 2025
Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota. Email:
Background: The use of the Ostial Flash balloon (Ostial Corporation) has received limited study in aorto-ostial chronic total occlusion (CTO) percutaneous coronary artery intervention (PCI).
Methods: The authors evaluated the outcomes of Ostial Flash balloon use in a large CTO-PCI registry (PROGRESS-CTO, NCT02061436).
Results: The Ostial Flash balloon was used in 54 of 907 aorto-ostial CTO PCIs in 905 patients (6.
Clin Pharmacokinet
January 2025
College of Pharmacy, Kyungsung University, 309, Suyeong-ro, Nam-gu, Busan, 48434, Republic of Korea.
Background And Objective: Telmisartan exhibits significant pharmacokinetic (PK) variability, but it remains unclear whether its PK profile is altered in hypertensive patients. This study aimed to characterize telmisartan PKs by conducting a meta-analysis and developing a pooled population PK model based on data from healthy subjects and hypertensive patients.
Methods: Relevant literature was identified by a systematic approach.
Curr Hypertens Rep
January 2025
Department of Pharmacy, The Second Clinical Medical College, The First Affiliated Hospital, Shenzhen People's Hospital, Jinan University, Southern University of Science and Technology), Shenzhen, China.
Purpose Of Review: To review currently existing knowledge on a new type of antihypertensive treatment, small interfering RNA (siRNA) targeting hepatic angiotensinogen.
Recent Findings: Targeting angiotensinogen synthesis in the liver with siRNA allows reaching a suppression of renin-angiotensin system (RAS) activity for up to 6 months after 1 injection. This might revolutionize antihypertensive treatment, as it could overcome non-adherence, the major reason for inadequate blood pressure control.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!